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OBJECTIVES: To compare the strength of the association
between depression and mortality between elderly and
younger individuals with diabetes mellitus.
DESIGN: A survival analysis conducted in a longitudinal
cohort study of persons with diabetes mellitus to test the
association between depression and mortality in older
(≥65) and younger (18–65) adults.
SETTING: Managed care.
PARTICIPANTS: Persons aged 18 and older with diabetes
mellitus who participated in the Wave 2 survey of the
Translating Research Into Action for Diabetes (TRIAD)
Study (N = 3,341).
MEASUREMENTS: The primary outcome was mortality
risk, which was measured as days until death using linked
data from the National Death Index. Depression was mea-
sured using the Patient Health Questionnaire.
RESULTS: After controlling for age, sex, race and ethnic-
ity, income, and other comorbidities, mortality risk in per-
sons with diabetes mellitus was 49% higher in those with
depression than in those without, although results varied
according to age. After controlling for the same variables,
mortality risk in persons aged 65 and older with depres-
sion was 78% greater than in those without. For those
younger than 65, the effect of depression on mortality was
smaller and not statistically significant.
CONCLUSION: This analysis suggests that the effect of
depression on mortality in persons with diabetes mellitus
is most significant for older adults. Because there is
evidence in the literature that treatment of depression in
elderly adults can lead to lower mortality, these results
may suggest that older adults with diabetes mellitus should
be considered a high-priority population for depression
screening and treatment. J Am Geriatr Soc 62:1017–1022,
2014.
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As of 2011, 25.8 million children and adults in the Uni-ted States had diabetes mellitus, and 79 million had
pre-diabetes mellitus.1 Persons with diabetes mellitus have
a mortality rate that is twice as high as persons of similar
age without diabetes mellitus.1 Individuals with diabetes
mellitus have also been found to have twice the odds of
being depressed as those without diabetes mellitus.2 In a
population of persons with type 2 diabetes mellitus in an
integrated healthcare delivery system in Washington State,
it was found that persons with depression had a signifi-
cantly higher mortality risk than those without, and the
greater risk was not limited to cardiovascular causes.3
Other studies, including those limited to elderly popula-
tions with diabetes mellitus, have found similar results.4–8
None of the prior studies examined the effect modifi-
cation that increasing age has on depression-related
mortality. No prior studies in this area have specifically
examined differences in the association between depression
and mortality in younger and older populations with dia-
betes mellitus. Thus, although the literature is consistent
that depression is associated with greater mortality in peo-
ple with diabetes mellitus, it does not adequately show
how this effect may vary with age. Using data from the
Translating Research Into Action for Diabetes (TRIAD)
Study, the association between depression and mortality in
persons with diabetes mellitus was examined, stratified
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according to age (<65 vs ≥65). Given the effects of age-
related comorbidities and the risk of depression-related
nonadherence to diabetes mellitus care in elderly adults, it
was hypothesized that the magnitude of the association
between depression and mortality would be greater in
older than younger adults.
METHODS
Study Design and Participants
TRIAD is a multicenter, prospective, longitudinal study of
persons with diabetes mellitus in managed care settings.9
The study cohort consisted of enrollees from 10 health
plans from eight states. Eligible persons were aged 18 and
older, community dwelling, and not pregnant; had had
diabetes mellitus for more than 1 year; spoke English or
Spanish; had been continuously enrolled in their health
insurance plan for 18 months or more; used at least one
diabetes mellitus–related medical service; and were able to
provide informed consent. The institutional review boards
at each participating site approved the study, and all par-
ticipants provided informed consent.
This report specifically analyzed data from the 2003
wave (Wave 2) of TRIAD, in which a depression screen
was administered to a sample of participants with diabetes
mellitus. These analyses include Wave 2 data from five of
the six study sites included in the original baseline survey.
The data were collected from TRIAD participants using a
mailed survey or a computer-assisted telephone interview
supplemented by a medical record review for the same
subjects to gather information on clinical variables.
TRIAD originally enrolled a sample of 11,927 adults,
with 8,334 completing the initial Wave 1 survey and medi-
cal record review. Although 6,760 persons completed the
Wave 2 survey, no medical chart data were available for
1,928 (28.5%) subjects, leaving 4,832 persons with both
sources of data. The sample size was further reduced by
591 persons because of missing data on at least one chart
variable in the analyses, leaving 4,241 persons with com-
plete medical record data. The sample size was further
reduced by 900 persons because of missing data on at least
one survey variable in the analyses, leaving an analytical
sample size of 3,341 (1,402, ≥65; 1,939, <65) with com-
plete survey and chart data.
Variables
The outcome variable was time to mortality, which was
measured as days until death after the interview date and
calculated using mortality data and dates of death obtained
from the National Death Index (NDI). The NDI service,
maintained by the National Center for Health Statistics, is
a computerized index of death record information com-
piled from state vital statistics offices and has been found
to have a high degree of validity.10 The NDI is updated
annually, approximately 12 months after the end of the
calendar year. Each TRIAD research site submitted the par-
ticipant’s first name, last name, Social Security number,
date of birth, and state of residence to the NDI. NDI
responded with a verification of death and the date of
death for all decedents. Each participant had 6 to 7 years
of mortality follow-up data, depending on their interview
date. NDI data were obtained through 2009.
The primary predictor variable was depression. Dep-
ression was measured using the Patient Health Question-
naire (PHQ-8),11 in which anyone with a score greater
than 9 points was classified as depressed. The Charlson
Comorbidity Index, which is associated with mortality
risk,12 was a covariate and was scored from comorbidity
data in the participant’s medical record. Other variables
used as covariates in the survival analyses included sex,
age, race and ethnicity, income, education, insulin treat-
ment, duration of diabetes mellitus, and marital status,
which came from the survey. Except for duration with dia-
betes mellitus and the Charlson Index, all of the indepen-
dent variables were treated as categorical to discern any
possible nonlinear effects. They were represented using a
series of indicators for each category, with one omitted
reference category. Age was divided into seven categories
(18–34, 35–44, 45–54, 55–64, 65–74 (reference category),
75–84, ≥85). Income was divided into four categories (<
$15,000, $15,000–39,999, $40,000–74,999, and ≥$75,000
(reference category)). Education was classified as less than
high school graduate, high school graduate, some college,
and college graduate or higher (reference category). The
categorical cut-points for these variables were selected to
ensure that there were sufficient participants in each cate-
gory for the analysis.
Because 28% of the Wave 2 sample did not have medi-
cal record data and could not be included in these analyses,
descriptive statistics were used to compare the mean age,
duration of diabetes mellitus, physical functioning score as
estimated using the PCS-12, and number of comorbidities to
estimate how representative the analytical sample was of the
original TRIADWave 2 cohort.
Statistical Analysis
Cox regression models, adjusted for demographic and
health variables and fixed effects for research site were
specified to determine the associations between depression
and time to death. Adjusted associations between each
predictor variable and days until death were expressed as
hazard ratios along with their associated 95% confidence
intervals. The same analysis was conducted stratified
according to age to compare the associations between
depression and mortality between the cohort aged 18 to
64 and that aged 65 and older. Finally, two sensitivity
analyses were conducted. The first added cardiovascular
disease, diabetic nephropathy, and smoking to the regres-
sion model, and the second examined the use of antide-
pressant medication.
RESULTS
To determine whether the analytical sample (N = 3,341)
was comparable with the larger sample of TRIAD partici-
pants completing Wave 2 surveys (n = 6,760), the age dis-
tributions in both groups were compared, and it was
found that 53% of the full Wave 2 sample and 58% of
the analytical sample was younger than 65. Duration with
diabetes mellitus, PCS12 score, and comorbidities were
also compared, and the magnitudes of these differences
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were small. Those in the analytical sample were approxi-
mately 3 years younger, had had diabetes mellitus for
1 year less, scored 0.5 points higher on the PCS12 (range
0–100), and had only a fraction of a comorbidity (0.16)
less than participants excluded from the analytical sample.
Descriptive statistics for important outcomes and
covariates in the groups with and without depression and
unadjusted tests of differences between the two groups for
each of these variables are shown in Table 1. All covari-
ates except duration with diabetes mellitus were found to
differ significantly between the groups with and without
depression. Unadjusted mortality differed significantly
between the groups with and without depression, with
27% of those with depression having died, compared with
18% of those without. Survival analyses of days until
death were conducted, controlling for the demographic
and clinical characteristics listed in Table 1. Table 2 shows
the results of these analyses expressed as three sets of haz-
ard ratios. The first shows the hazard ratios for the entire
cohort, which is similar to previous studies in the analyti-
cal methods and results.3–8 The estimates stratified accord-
ing to age are displayed in the second and third columns.
Before running the stratified analyses, the need for
stratification was evaluated by testing the equality of the
structure of the model between the age subsamples. A
significant difference in model structure was found
(chi-square = 60.82, P < .001), indicating the need for
stratification. For the analysis of the entire cohort, as
shown in the first column of Table 2, participants with
depression were 49% more likely to die on any given day
than those without even after controlling for age. These
results are similar to those of previous studies,3–7 although
in the age-stratified analyses that allow for the effects of
depression and the other predictors to vary for the older
and younger participants, persons aged 65 and older with
depression were nearly 80% more likely to die on any
given day than those without. In contrast, in the younger
population, the association between depression and mor-
tality was smaller and not statistically significant.
Two sensitivity analyses were conducted. In the first,
whether cardiovascular disease, diabetic nephropathy, or
smoking confounded the effect of depression on mortality
was examined. Although there was a significant associa-
tion between each of the three and mortality, their inclu-
sion in the model did not change the magnitude of the
association between depression and mortality. Because of
missing data and the resulting decrease in the number of
available observations (from 3,341 to 2,698), as well as
concerns that these measures may partly mediate the
effects of depression on mortality, these variables were
excluded from the main analyses.
Whether the use of depression medication caused a
change in the association of depression with mortality was
examined in the second sensitivity analysis. The results of
these analyses are shown in Table 3. Instead of using
depression (defined as having a PHQ-8 score >9) as a
variable, the association between mortality and having
depression and no antidepressant use, as well as between
mortality and having a history of antidepressant use within
the 18 months before the chart abstraction (with or with-
out current depression) was examined. The reference
group contained participants with no current depression (a
PHQ-8 ≤ 9) and no history of antidepressant use within
the 18 months before the chart abstraction. The results
showed that, in the entire cohort, the depressed–no antide-
pressant group and the antidepressant group had signifi-
cantly higher mortality risk than those who were not
depressed and had no history of antidepressant use. When
this analysis was replicated with the same age stratification
as the main analyses, the results showed that, although the
direction of the estimated effects remained the same,
the statistical significance changed substantially. Of those
younger than 65, neither the depressed–no antidepressant
group nor the antidepressant group had significantly
greater mortality risk than the reference group. In the
group aged 65 and older, the depressed–no antidepressant
group had 90% greater mortality than the reference group,
but those with a history of antidepressant use were not
statistically different from the reference group. Because of
Table 1. Demographic and Health Characteristics of
Study Cohort
Characteristic N
Not
Depressed Depresseda P-Value
Total,% 3,341 81.7 18.3
Female,% 1,777 50.6 64.9 <.001
Insulin
treatment,%
648 18.9 23.9 .002
Married or
living together,%
2,065 63.9 52.5 <.001
Age, %
18–34 69 2.0 2.5 <.001
35–44 254 7.0 10.2
45–54 688 19.6 25.1
55–64 928 27.3 29.8
65–74 885 27.7 21.3
75–84 483 15.4 10.2
≥85 34 1.0 1.0
Race and
ethnicity, %
White 1,890 57.2 53.8 .002
Hispanic 532 16.0 15.6
Black 599 17.0 22.1
Asian and
Pacific Islander
131 4.4 2.0
Other 189 5.5 6.6
Income, $,%
<15,000 818 20.7 41.3 <.001
15,000–39,999 1,073 32.1 32.1
40,000–74,999 821 26.0 18.2
≥75,000 629 21.2 8.4
Education,%
<High school
graduate
607 15.7 29.2 <.001
High school
graduate
897 26.4 29.0
Some college 1,072 32.9 28.4
≥College graduate 765 25.0 13.4
Years with diabetes
mellitus, mean
3,341 13.0 13.3 .50
Charlson Index,
mean
3,341 2.0 2.4 <.001
Deceased,%b 666 18.4 26.7 <.001
a Patient Health Questionnaire score > 9.
b Six- to 7-year follow-up depending on interview date.
JAGS JUNE 2014–VOL. 62, NO. 6 DIABETES MELLITUS, DEPRESSION, AND MORTALITY IN ELDERLY ADULTS 1019
missing data and the resulting decrease in the number of
observations (from 3,341 to 2,799), these results are
presented as a sensitivity analysis rather than as the main
analysis.
DISCUSSION
This study examined the association between depression
and mortality in a large, diverse group of persons with dia-
betes mellitus. It also examined these associations stratifying
according to age. Results from the age-stratified analyses
suggest that the elderly population may be driving the signif-
icant associations between depression and mortality found
in other full-population studies. Being aged 65 and older
had a substantial effect modification on the relationship
between depression and mortality. This effect modification
is missed when controlling for age alone. There may be
differential attrition rates according to age, but if partici-
pants with the most-severe depression were more likely to
die before the Wave 2 survey, then the observed significance
may be an underestimate. In contrast, if participants with
greater comorbidity and older age had an observed likeli-
hood of dying from other conditions, the group of healthier
survivors at Wave 2 may have had a greater observed mag-
nitude of association between depression and mortality than
in the cohort overall.
Because individuals with depression are less likely to
adhere to their medications than those without regardless
of age,7,13–15 the resulting higher depression-associated
mortality in elderly adults could be due to a stronger effect
of nonadherence to diabetes mellitus medication on mortal-
ity in this group than in the younger population. Individuals
with depression have also been shown to have low levels of
adherence to critical diabetes mellitus care treatment such
Table 2. Survival Analyses of Persons with Diabetes Mellitus Stratified According to Age
Hazard Ratio (95% Confidence Interval)
Variable Entire Cohort, N = 3,341 Age≥65, n = 1,402 Age<65, n = 1,939
Depresseda 1.49 (1.24–1.80) 1.78 (1.39–2.27) 1.15 (0.86–1.54)
Female 0.53 (0.44–0.62) 0.61 (0.49–0.76) 0.45 (0.34–0.59)
Duration with diabetes mellitus 1.01 (1.00–1.01) 1.01 (1.00–1.02) 1.00 (0.99–1.02)
Insulin treatment 1.20 (0.98–1.46) 1.10 (0.84–1.44) 1.31 (0.97–1.78)
Married or living together 0.77 (0.65–0.92) 0.83 (0.66–1.04) 0.68 (0.51–0.91)
Charlson Index 1.31 (1.26–1.36) 1.28 (1.21–1.35) 1.39 (1.30–1.48)
Age
18–34 0.08 (0.01–0.56) Reference
35–44 0.15 (0.07–0.31) 1.96 (0.24–16.02)
45–54 0.58 (0.43–0.76) 7.47 (1.03–54.09)
55–64 0.81 (0.66–1.01) 10.26 (1.42–73.94)
65–74 Reference Reference
75–84 1.69 (1.39–2.07) 1.69 (1.38–2.07)
≥85 4.78 (3.12–7.33) 4.53 (2.94–6.98)
Race or ethnicity (reference white)
Hispanic 0.67 (0.51–0.88) 0.83 (0.60–1.15) 0.45 (0.27–0.74)
Black 0.67 (0.53–0.85) 0.55 (0.38–0.79) 0.77 (0.55–1.08)
Asian and Pacific Islander 0.20 (0.07–0.54) 0.29 (0.09–1.92) 0.11 (0.02–0.81)
Other 0.89 (0.65–1.23) 1.08 (0.74–1.58) 0.58 (0.32–1.05)
Income, $ (reference ≥$75,000)
<15,000 2.39 (1.65–3.45) 2.01 (1.25–3.26) 2.83 (1.58–5.08)
15,000–39,999 2.38 (1.72–3.30) 1.99 (1.28–3.07) 3.08 (1.86–5.11)
40,000–74,999 1.71 (1.22–2.39) 1.80 (1.15–2.84) 1.35 (0.80–2.28)
Education (reference ≥college graduate)
< High school graduate 1.04 (0.80–1.37) 0.95 (0.68–1.33) 1.18 (0.73–1.90)
High school graduate 0.95 (0.74–1.22) 0.92 (0.68–1.26) 0.96 (0.62–1.48)
Some college 1.01 (0.80–1.28) 0.97 (0.71–1.31) 1.07 (0.72–1.59)
a Patient Health Questionnaire score >9.
Table 3. Survival Analyses of Persons With Diabetes Mellitus Overall and Stratified According to Age and Antide-
pressant Use
Variable
Entire Cohort, N = 2,799 Older Cohort, n = 1,119 Younger Cohort, n = 1,680
n (%) HR (95% CI) n (%) HR (95% CI) n (%) HR (95% CI)
Depressed---no history of antidepressant use 309 (11) 1.65 (1.30–2.11) 113 (10) 1.9 (1.39–2.59) 196 (12) 1.27 (0.86–1.89)
History of antidepressant use 525 (19) 1.30 (1.04–1.63) 142 (13) 1.12 (0.81–1.56) 383 (23) 1.38 (0.99–1.93)
Reference category was a Patient Health Questionnaire score ≤9 (not depressed) and no history of antidepressant use.
HR = hazard ratio; CI = confidence interval.
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as diet, exercise, and a glucose self-monitoring regimen.13,15
This nonadherence can be particularly detrimental to
elderly adults, who may already have age-related comorbid-
ities. These age-related changes include physical and psy-
chological changes that can have a negative effect on the
severity of depression and other diabetic factors.7 These
cyclical effects may be what caused this drastically greater
mortality risk associated with depression in older adults
than in younger cohorts of individuals with diabetes
mellitus.
There is evidence of undertreatment of depression in
primary care settings in elderly persons.16,17 The results of
the sensitivity analysis in Table 3 regarding antidepressant
use suggests that effective depression treatment may greatly
attenuate the strong link between depression and mortality
in elderly person with diabetes mellitus. It is also possible
that lower rates of treatment for depression may contribute
to the difference in the magnitude of the association between
depression and mortality in older adults and that in younger
adults. An alternative hypothesis could be that depression is
simply a prodromal marker for disease severity and does not
have a causal effect on mortality. Several studies have found
a strong association between disease severity and comorbid
depression in individuals with diabetes mellitus but have
concluded that further research is needed to determine the
pathways and biological mechanisms associated with this
interaction.18–21 It was attempted in the current study to
control for the possibility of confounding by controlling for
duration with diabetes mellitus and Charlson Index. It was
not possible to control for cognitive impairment. As previ-
ous studies have shown, depression, and cognitive impair-
ment are linked, especially in individuals with diabetes
mellitus.22–24 Therefore, the observed effect of depression
on mortality in the elderly group may be partially due to
unmeasured cognitive impairment, although the fact that
each individual in the sample was required to give informed
consent to be included in the study and to complete a
45-minute survey without assistance, thus likely excluding
those with major cognitive impairment, somewhat mitigated
this limitation.
This study has some limitations. First, the measure for
depression was the PHQ-8, which is a screening test and
not a diagnostic tool. Although PHQ-8 scores above 9 are
correlated with depression,11 they do not confirm the diag-
nosis. Also, information was not available in TRIAD about
individuals who were receiving treatment other than phar-
macotherapy for their depression. Second, it was not possi-
ble to control for other potentially important unmeasured
factors such as family history of other diseases or other
environmental factors. Third, the sample included only
TRIAD participants for whom Wave 2 data were collected
and only for those who had complete data capture.
Finally, because the sample was limited to persons with
diabetes mellitus with managed care insurance, it may not
generalize to those with other forms of coverage or to
those who are uninsured.
These results, along with the earlier evidence of com-
plications18 and greater medical costs25 that result from
untreated depression in individuals with diabetes mellitus,
reinforce the importance of screening for depression, par-
ticularly in older adults. A previous study analyzing the
effectiveness of depression diagnosis and treatment found
that older individuals with depression and diabetes mel-
litus were less likely to die within a 5-year interval if their
primary care clinics were implementing depression care
management programs.26 These results, combined with the
hypothesis-generating finding that older adults with diabe-
tes mellitus, depression, and a history of antidepressant
treatment did not have higher mortality than those without
depression, suggests that clinical recognition and treatment
of depression may be particularly important for older
adults with diabetes mellitus. Using depression screens
such as the PHQ-8 or even the abbreviated PHQ-227 can
be an effective way of recognizing depression before it
results in unnecessary health risks that can lead to death.
Older adults with diabetes mellitus, in virtually all clinical
settings, should be considered a top priority for these
screenings. Using a two-item screen such as the PHQ-2
will help physicians identify individuals with diabetes mel-
litus at high risk of depression during a routine visit and
should facilitate timely diagnosis with the PHQ-9 or refer-
ral to confirm diagnosis and treat if needed,6 but further
research will need to be conducted to determine the best
practices for the treatment of depression in individuals
with diabetes mellitus because there are mixed reviews on
the effectiveness of treatment as depression worsens.28–30
Therefore, it is of vital importance, particularly in elderly
adults, to screen and treat depression as soon as possible.
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